Issue: August 2018
August 09, 2018
1 min read
Save

Trial Scorecard: PROACT

Issue: August 2018
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers assessed whether lower-intensity warfarin or dual antiplatelet therapy were feasible vs. standard-intensity warfarin after surgical aortic valve replacement with a mechanical valve (On-X, On-X Technologies).

Trial Scorecard: PROACT